18F-PSMA-1007 ZRP ≥ 40 MBq / mL, Injektionslösung
7680674040019
CH-67404
Injektionslösung
Associated product:
18F-PSMA-1007 ZRP >= 40 MBq / mL
1 / 2
google
Article details
- Package size
- 1
- Selling units
- 1
- Measure
- Durchstechflasche(n)
- Galenic form
- Injektionslösung
- Galenic group
- Injektion/Infusion
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
(18F)-PSMA-1007
|
- | Substance | Wirkstoff (Principe actif) |
|
dinatrii phosphas
|
- | Substance | HNIDK |
|
kalii dihydrogenophosphas
|
- | Substance | HNIDK |
|
natrii chloridum
|
- | Substance | HNIDK |
|
kalii chloridum
|
- | Substance | HNIDK |
|
natrii ascorbas
|
- | Substance | HNIDK |
|
ethanolum
|
0.0375 ML | Substance | HBESI |
|
aqua ad iniectabile
|
- | Substance | HNIDK |
|
natrium
|
4.2 MG | Substance | HBESI |
Authorization holder
Universitätsspital Zürich
8091 Zürich
Authorization information
- Swissmedic authorization number
- 67404
- Drug name
- 18F-PSMA-1007 ZRP, Injektionslösung
- Galenic form
- LSINJ
- ATC Code
- V09IX17
- Authorization status
- Z
- Dispensing category
- A
- First authorization
- 11/06/2024
- Authorization expiration date
- 10/06/2029
- IT Number
- 17.01.9.
- Domain
- Human medicine
Package details
- Description (FR)
- 18F-PSMA-1007 ZRP >= 40 MBq / mL
- Description (DE)
- 18F-PSMA-1007 ZRP >= 40 MBq / mL
- Market launch
- 11/06/2024
- Market withdrawal
- 10/06/2029
- Narcotic (BTM)
- No